Athira Pharma (LONA) Financials

Athira Pharma’s latest quarter shows a company with a very large cash position, but also one that is still burning a significant amount of cash while generating no revenue. For Q1 2026, Athira reported $0 in revenue and a net loss of $32.9 million, or $1.73 per share. That is a big loss, but it was smaller than the $82.9 million loss in Q4 2025 and also improved from the $6.6 million loss in Q3 2025 on a quarter-to-quarter basis with more stable operations.

One of the biggest positives is liquidity. As of March 31, 2026, Athira held $32.8 million in cash and $34.8 million in short-term investments, for roughly $67.7 million in liquid assets. That helped the company finish the quarter with $71.6 million in total assets versus $22.3 million in total liabilities, leaving $49.3 million in common equity.

However, the balance sheet also shows how quickly that cushion can shrink. Cash and investments fell from about $74.2 million at the end of Q3 2025 to about $67.7 million at the end of Q1 2026. Earlier in 2025, the company had much more cash, including $128.6 million in total current assets at Q1 2024, so the trend over the last year and a half has been clearly downward.

• Strong liquidity position remains the key support: cash plus short-term investments totaled about $67.7 million at the end of Q1 2026.
• Low debt burden: total liabilities were only $22.3 million, modest compared with assets and cash holdings.
• Equity remains positive: total common equity was $49.3 million in Q1 2026.
• Operating cash burn improved versus late 2025: operating cash outflow was $20.9 million in Q1 2026, better than $19.4 million in Q4 2025 after a much larger net loss.
• No revenue is still being generated: Athira reported $0 revenue in every quarter shown.
• The business remains research-heavy: R&D spending was $11.3 million in Q1 2026, down sharply from $74.8 million in Q4 2025 and $22.2 million in Q2 2025.
• Balance sheet structure is heavily equity-funded: common stock is very large while retained earnings remain deeply negative, reflecting years of cumulative losses.
• Continued losses are significant: Q1 2026 net loss of $32.9 million remains large for a company with no sales.
• Cash is trending lower year over year: cash and investments are well below the levels seen in 2024.
• Ongoing cash burn raises financing risk: investing and operating activities continue to consume cash, which could eventually pressure the company to raise capital.

Looking at the broader trend, Athira’s quarterly losses have been volatile but consistently negative. In 2024 and 2025, quarterly net losses ranged from about $6.6 million to $82.9 million, while operating cash flow was negative in most quarters. The standout exception was Q3 2025, when the company generated positive investing cash flow, but that was driven by investment maturities rather than profitable operations.

Bottom line: Athira Pharma currently looks like a cash-rich, pre-revenue biotech with a relatively clean balance sheet, but the core challenge remains unchanged: it is still burning cash without sales. Investors will likely focus on whether the company can preserve its cash runway and make progress on its pipeline before needing additional financing.